Aclaris Therapeutics (ACRS) Other Operating Expenses (2016 - 2026)

Aclaris Therapeutics' Other Operating Expenses history runs 11 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 1.54% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $9.6 million, a 90.63% decrease from a year earlier, with the FY2025 full-year figure at $9.6 million, down 90.86% from the prior year.
• Other Operating Expenses retreated to $1.8 million in Q1 2026 per ACRS's latest filing, from $1.9 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $94.9 million in Q4 2024 and bottomed at -$13.2 million in Q4 2023.
• The 5-year median for Other Operating Expenses is $2.1 million (2024), against an average of $7.7 million.
• Biggest YoY gain for Other Operating Expenses was 2475.56% in 2023; the steepest drop was 253.74% in 2023.
• Year by year, Other Operating Expenses stood at $8.6 million in 2022, then tumbled by 253.74% to -$13.2 million in 2023, then soared by 816.65% to $94.9 million in 2024, then tumbled by 98.03% to $1.9 million in 2025, then retreated by 4.33% to $1.8 million in 2026.
• Per Business Quant, the three latest ACRS Other Operating Expenses figures stand at $1.8 million (Q1 2026), $1.9 million (Q4 2025), and $2.5 million (Q3 2025).